Ultragenyx Pharmaceutical Q3 2026 Earnings Date & Estimates

Ultragenyx Pharmaceutical (NASDAQ:RARE) is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. The company targets conditions with limited or no treatment options, including metabolic disorders, skeletal diseases and other inherited conditions. Its work includes the development of medicines, biologic therapies and gene therapy candidates intended to address the underlying causes or significant symptoms of these disorders.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Dojolvi (triheptanoin), a medical food used to manage long-chain fatty acid oxidation disorders; and Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII. The company also maintains a pipeline of investigational therapies, including gene therapy programs for rare diseases.

Founded in 2010 by physician-scientist Emil Kakkis, Ultragenyx is headquartered in Novato, California. Kakkis serves as the company’s chief executive officer and has led its focus on rare-disease drug development. Ultragenyx serves patients and healthcare providers in the United States and international markets through its commercial operations, partnerships and regional distribution arrangements.